Rhelion Life Sciences (STU:4YX0) Inventories, Raw Materials & Components: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Inventories, Raw Materials & Components?

Rhelion Life Sciences STU:4YX0 -71.43% Inventories, Raw Materials & Components is €0.00 Mil as of Jun. 2026. The stock has 6 warning signs investors should review.

Rhelion Life Sciences's inventories, raw materials & components for the quarter that ended in Jun. 2026 was €0.00 Mil.

Rhelion Life Sciences's annual raw materials declined from Mar. 2024 (€0.08 Mil) to Mar. 2025 (€0.01 Mil) and declined from Mar. 2025 (€0.01 Mil) to Mar. 2026 (€0.00 Mil).

Rhelion Life Sciences Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Inventories, Raw Materials & Components Chart

Rhelion Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.11 0.08 0.01 0.00

Rhelion Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 0.00

Rhelion Life Sciences Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Rhelion Life Sciences (STU:4YX0) has a Inventories, Raw Materials & Components of €0.00 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Inventories, Raw Materials & Components too high?
Rhelion Life Sciences' current Inventories, Raw Materials & Components is €0.00 Mil.
How does Rhelion Life Sciences' Inventories, Raw Materials & Components compare to ZTS?
Rhelion Life Sciences' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Rhelion Life Sciences (STU:4YX0) has a current Inventories, Raw Materials & Components of €0.00 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 99% below its estimated fair value. The current Inventories, Raw Materials & Components is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current Inventories, Raw Materials & Components is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Rhelion Life Sciences Corp is a pharmaceutical research and development company focused on natural psychedelic medicines for psychiatric and neurological conditions. The company is engaged in the discovery and development of drug candidates derived from naturally occurring psychoactive compounds, targeting indications such as depression, anxiety, post-traumatic stress disorder, and other mental health disorders. Its activities center on preclinical and clinical research, formulation development, and regulatory pathways for psychedelic-based therapeutics. As a development-stage company, Rhelion does not yet market approved products and relies on equity financing, grants, and partnership arrangements to fund its research programs. Its primary market is the United States, with potential expansion into other jurisdictions where regulatory frameworks permit psychedelic-assisted therapy research and commercialization. The company operates in the emerging psychedelic medicine sector, competing with other biopharmaceutical firms pursuing synthetic and natural psychedelic compounds.